Modern Retina Newsletter

To view this email as a web page, click here.

Focus on DME/DR

Lipid-lowering drugs, lower DR risk may go hand in hand

Learn how patients with type 2 diabetes benefited from lipid-lowering medications in a large retrospective cohort study.

Anti-VEGF expansion treats all DR stages

See what an expanded indication for aflibercept means for the treatment of patients with diabetic retinopathy.

Find out

Cataract surgery in patients with diabetes: No time like the present

Here’s why cataract surgery should not be delayed based on the HbA1c levels in patients with diabetic eye disease.

Learn more

What strict adherence means for successful PDR results

Image-reading accuracy Increases with deep-learning DR algorithms

Determining DR progression: Much work still needs to be done

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.